It has also been shown that Nrf2 can be used to regulate Ferroptosis to treat neurodegenerative diseases (Song and Long, 2020), delay the progression of diabetic nephropathy (DN) (Li S. et al., 2021) and prevent acute lung injury due to intestinal ischemia/reperfusion (Dong et al., 2020), and it has been found that proanthocyanidins (Zhou et al., 2020), alginose (Gong et al., 2022), metformin (Wang H. et al., 2020), and growth differentiation factor-15 (Xia et al., 2022) are all inhibited by NRF2. This evidence concerns the gene NFE2L2 and ischemia.